Acadia Pharmaceuticals Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DR6.F | ATAI | NEU.AX | AXSM | PRAX | B9A.F | |
|---|---|---|---|---|---|---|
| Market cap | 3.05B | — | 2.50B | 8.36B | 7.38B | 2.35B |
| P/E (TTM) | 9.5 | — | 131.3 | — | — | 265.0 |
| Forward P/E | -19.2 | — | 33.0 | 39.5 | -27.8 | — |
| Price/book | 2.6 | — | 7.5 | 100.2 | 5.5 | 1.2 |
| Dividend yield | — | — | 1.53% | — | — | 0.69% |
| 1-year change | −13.36% | — | −8.27% | +23.02% | +39.19% | −6.90% |
| Today | 0.00% | 0.00% | +0.41% | +2.42% | +1.66% | −0.08% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All DR6.F news ›ACADIA Pharmaceuticals’ (ACAD) Buy Rating Reiterated at Needham & Company LLC
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They presently have a $35.00 price…
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to “Hold” at Wall Street Zen
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Monday, Wall Street Zen reports. View Our Latest Stock Report on ACAD ACADIA…
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
PR Newswire NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("Acadia" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle…
ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to “Neutral” at UBS Group
Posted by Kim Johansen on Oct 13th, 2026 ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday,…
Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Shareholders to Inquire about Securities Investigation
ACCESS Newswire Bronstein, Gewirtz & Grossman, LLC Encourages ACADIA Pharmaceuticals Inc. (ACAD) Shareholders to Inquire about Securities Investigation Monday, 12 October 2026 01:00 PM What's Next for Acadia Investors? No Cost to Acadia…
Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Investors to Connect
ACCESS Newswire Bronstein, Gewirtz & Grossman, LLC Is Investigating ACADIA Pharmaceuticals Inc. (ACAD) And Encourages Investors to Connect Sunday, 11 October 2026 01:00 PM What's Next for Acadia Investors? No Cost to Acadia Investors We,…
Acadia Pharmaceuticals | Science & Technology
Cummings, J. et al. (2014) ‘Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial’, The Lancet, 383(9916), pp. 533–540. Glaze, D.G. et al. (2019) ‘A Double-Blind, Randomized,…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
defenseworld.net7
-
accessnewswire.com2
-
markets.businessinsider.com2
-
prnewswire.com2
-
biospace.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 21 articles, not a forecast.